Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Stock Information for Syros Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.